ALPHAMAB ONCOLOGY
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for cancer treatment with multiple in-house proprietary platforms in bispecifics, protein engineering and antibody screening, Alphamab Oncology has built a robust pipeline in oncology/ immunology, and they are striving to develop next-generation or best-in-class medicines to address unmet medical needs globally.
ALPHAMAB ONCOLOGY
Social Links:
Industry:
Biotechnology Clinical Trials Health Care Manufacturing Oncology Pharmaceutical Therapeutics
Founded:
2009-01-01
Status:
Active
Contact:
+86-512 6285 0800
Email Addresses:
[email protected]
Total Funding:
160 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro SPF SSL By Default Mobile Non Scaleable Content Pound Sterling ASP.NET IIS
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Apollo 24/7
Apollo 24|7 is a mobile app and digital healthcare platform.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
BiolineRx
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel.
Medannex Ltd
Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.
Median Technologies
MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, screening, and clinical practice.
Soothe Healthcare
Soothe Healthcare is an engaged in manufacturing, marketing & distributing Consumer-Healthcare products.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
PAG
PAG investment in Series B - Alphamab Oncology
China Venture Capital
China Venture Capital investment in Series B - Alphamab Oncology
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Series B - Alphamab Oncology
Adrian Cheng
Adrian Cheng investment in Series B - Alphamab Oncology
Advantech Capital
Advantech Capital investment in Series B - Alphamab Oncology
Advantech Capital
Advantech Capital investment in Series A - Alphamab Oncology
Heritage Provider Network
Heritage Provider Network investment in Series A - Alphamab Oncology
China Venture Capital
China Venture Capital investment in Series A - Alphamab Oncology
OrbiMed
OrbiMed investment in Series A - Alphamab Oncology
PAG
PAG investment in Series A - Alphamab Oncology
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-03-01 | Sidi Diagnostics | Alphamab Oncology investment in Venture Round - Sidi Diagnostics | 280 M CNY |
| 2016-03-21 | SmartNuclide | Alphamab Oncology investment in Angel Round - SmartNuclide | 3 M CNY |
More informations about "Alphamab Oncology"
Alphamab Oncology - Crunchbase Investor Profile & Investments
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization of world-class innovative therapeutics for …See details»
Alphamab Oncology Presentation
Alphamab Oncology Presentation January 2021. Disclaimer This presentation has been prepared by Alphamab Oncology (the “Company”)solely for use at the presentation held in January …See details»
Xu Ting – Founder, Chairman & CEO, Alphamab …
Oct 5, 2024 HKEX-main board listed Alphamab Oncology is one of China's leading biotech success stories, having developed and marketed the world's first subcutaneously injectable PD-L1 inhibitor. ... By focusing on differentiation …See details»
Alphamab Oncology - Funding, Financials, Valuation & Investors
Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development manufacturing and commercialization. Search Crunchbase. ... How much …See details»
9966.HK - | Stock Price & Latest News | Reuters
2 days ago Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in …See details»
Xu Ting - Founder & CEO @ Alphamab Oncology - Crunchbase
Primary Organization . Alphamab Oncology . Gender Male; Also Known As Ting Xu; Ting Xu is the founder of Alphamab Co., focusing on the development of innovative protein/antibody …See details»
Alphamab Oncology Presents the Latest Clinical Data of Anti-Her2 ...
Nov 11, 2024 Alphamab Oncology announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 …See details»
Late-Breaking Abstract! Alphamab Oncology Presented the Latest …
Nov 11, 2024 Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation …See details»
Alphamab Oncology updated data from two studies of KN026 in …
Oct 24, 2023 Alphamab Oncology (stock code: 9966.HK) announced the results of two studies of HER2 bispecific antibody KN026 at the European Society of Medical Oncology (ESMO) …See details»
Alphamab Oncology Announces New Data from Multiple Studies …
SUZHOU, China, Oct. 24, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 at the …See details»
Alphamab Oncology updated clinical research data for KN026 in ...
SUZHOU, China, June 6, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that updated data from the phase II clinical study of the chemo-free regimen of …See details»
Alphamab Oncology updated data from two studies of KN026 in …
SUZHOU, China, Oct. 24, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the results of two studies of HER2 bispecific antibody KN026 at the European …See details»
Alphamab Oncology Announces New Data from Multiple Studies …
Oct 24, 2023 Alphamab Oncology (stock code: 9966.HK) announced the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 at the European Society of Medical Oncology …See details»
Kevin S. Choe, MD, PhD - Radiation Oncology
He has published numerous research articles and book chapters on cancer biology and clinical oncology, some of which have been featured in the New York Times and NPR. His work has …See details»
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 ...
Jun 3, 2024 Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate …See details»
Woodbridge Office - Virginia Cancer Specialists
Address. 2280 Opitz Boulevard, Suite 130 Woodbridge, VA 22191. Phone: (571) 350-8400 Fax: (703) 897-7938See details»
Geoffrey D. Moorer, MD - Virginia Cancer Specialists
Feb 1, 2024 Dr. Moorer holds memberships in several organizations including the American Society of Clinical Oncology, the American Society of Hematology and the National Medical …See details»
Alphamab Oncology Announces the First Patient Dosed in a Phase …
May 22, 2024 Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel …See details»
Christopher Johnson, MD | Inova
Dr. C. Bryce Johnson is a specialty care physician board certified in radiation oncology. He joined Inova Health System in 2021 and has been practicing since 2017. Prior to joining Inova, Dr. …See details»